These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 21991908)

  • 1. Antitrypanosomal therapy for chronic Chagas' disease.
    Garcia-Bournissen F; Altcheh J
    N Engl J Med; 2011 Sep; 365(13):1258; author reply 1259. PubMed ID: 21991908
    [No Abstract]   [Full Text] [Related]  

  • 2. Antitrypanosomal therapy for chronic Chagas' disease.
    Bestetti RB; Cardinalli-Neto A
    N Engl J Med; 2011 Sep; 365(13):1258-9; author reply 1259. PubMed ID: 21991909
    [No Abstract]   [Full Text] [Related]  

  • 3. Antitrypanosomal therapy for chronic Chagas' disease.
    Bern C
    N Engl J Med; 2011 Jun; 364(26):2527-34. PubMed ID: 21714649
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of immunosuppression and benzonidazole on Trypanosoma cruzi parasitism during experimental acute Chagas' disease.
    Okumura M; Mester M; Iriya K; Amato Neto V; Gama-Rodrigues J
    Transplant Proc; 1994 Jun; 26(3):1587-9. PubMed ID: 8030049
    [No Abstract]   [Full Text] [Related]  

  • 5. [Treatment of Chagas' disease].
    Apt W
    Rev Med Chil; 1985 Feb; 113(2):162-6. PubMed ID: 3936147
    [No Abstract]   [Full Text] [Related]  

  • 6. Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives.
    Braga MS; Lauria-Pires L; Argañaraz ER; Nascimento RJ; Teixeira AR
    Rev Inst Med Trop Sao Paulo; 2000; 42(3):157-61. PubMed ID: 10887376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An update on benznidazole for the treatment of patients with Chagas disease.
    Thakare R; Dasgupta A; Chopra S
    Drugs Today (Barc); 2018 Jan; 54(1):15-23. PubMed ID: 29569658
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Authors' reply: Vitamins in the treatment of chronic Chagas disease: adjuvant antiparasitary or antioxidant therapy?
    Andrade MC; Oliveira Mde F; Nagao-Dias AT; Coêlho IC; Cândido Dda S; Freitas EC; Coelho HL; Bezerra FS
    Rev Soc Bras Med Trop; 2014; 47(5):670-1. PubMed ID: 25467276
    [No Abstract]   [Full Text] [Related]  

  • 9. The role of benznidazole with cyanocobalamin and ascorbic acid in treating the chronic phase of Chagas disease.
    Ghobadifar MA; Kalani N; Gitiforouz M; Mosallanejad Z
    Rev Soc Bras Med Trop; 2014; 47(5):669. PubMed ID: 25467275
    [No Abstract]   [Full Text] [Related]  

  • 10. Comparative efficacies of TAK-187, a long-lasting ergosterol biosynthesis inhibitor, and benznidazole in preventing cardiac damage in a murine model of Chagas' disease.
    Corrales M; Cardozo R; Segura MA; Urbina JA; Basombrío MA
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1556-60. PubMed ID: 15793138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recognition for Chagas disease.
    Burki T
    Lancet Infect Dis; 2019 Jul; 19(7):699. PubMed ID: 31250822
    [No Abstract]   [Full Text] [Related]  

  • 12. Criteria of Chagas disease cure.
    Cançado JR
    Mem Inst Oswaldo Cruz; 1999; 94 Suppl 1():331-5. PubMed ID: 10677750
    [No Abstract]   [Full Text] [Related]  

  • 13. Nifurtimox chemotherapy: collateral effects in treated Trypanosoma cruzi infected patients.
    Murcia L; Carrilero B; Albajar Viñas P; Segovia M
    Rev Esp Quimioter; 2012 Mar; 25(1):74-5. PubMed ID: 22488545
    [No Abstract]   [Full Text] [Related]  

  • 14. Reactivation of chronic Chagas' disease following allogeneic bone marrow transplantation and successful pre-emptive therapy with benznidazole.
    Altclas J; Sinagra A; Jaimovich G; Salgueira C; Luna C; Requejo A; Milovic V; De Rissio A; Feldman L; Riarte A
    Transpl Infect Dis; 1999 Jun; 1(2):135-7. PubMed ID: 11428981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations.
    Garcia S; Ramos CO; Senra JF; Vilas-Boas F; Rodrigues MM; Campos-de-Carvalho AC; Ribeiro-Dos-Santos R; Soares MB
    Antimicrob Agents Chemother; 2005 Apr; 49(4):1521-8. PubMed ID: 15793134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy of Chagas' disease: status and new developments.
    Cerecetto H; González M
    Curr Top Med Chem; 2002 Nov; 2(11):1187-213. PubMed ID: 12171581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Treatment of chronic Chagas' disease. Is the etiological treatment effective?].
    Rassi A; Rassi Júnior A
    Arq Bras Cardiol; 1998 Oct; 71(4):643-6. PubMed ID: 10347944
    [No Abstract]   [Full Text] [Related]  

  • 18. The dog as model for chemotherapy of the Chagas' disease.
    Guedes PM; Veloso VM; Tafuri WL; Galvão LM; Carneiro CM; Lana Md; Chiari E; Ataide Soares K; Bahia MT
    Acta Trop; 2002 Oct; 84(1):9-17. PubMed ID: 12387906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Should benznidazole be used in chronic Chagas' disease?
    Bestetti RB
    Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760
    [No Abstract]   [Full Text] [Related]  

  • 20. Shift of excretory-secretory immunogens of Trypanosoma cruzi during human Chagas' disease.
    Jazín EE; Luquetti AO; Rassi A; Frasch AC
    Infect Immun; 1991 Jun; 59(6):2189-91. PubMed ID: 1903775
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.